Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study von Furman, Richard R, Dr, Eradat, Herbert A, MD, DiRienzo, Christine G, PhD, Hofmeister, Craig C, MD, Hayman, Suzanne R, MD, Leonard, John P, Prof, Coleman, Morton, Prof, Advani, Ranjana, Prof, Chanan-Khan, Asher, MD, Switzky, Julie, MSN, Liao, Qiming M, PhD, Shah, Damini, BSc, Jewell, Roxanne C, PhD, Lisby, Steen, MD, Lin, Thomas S, MD

Volltext

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial von Sekeres, Mikkael A., Montesinos, Pau, Novak, Jan, Wang, Jianxiang, Jeyakumar, Deepa, Tomlinson, Benjamin, Mayer, Jiri, Jou, Erin, Robak, Tadeusz, Taussig, David C., Dombret, Hervé, Merchant, Akil, Shaik, Naveed, O’Brien, Thomas, Roh, Whijae, Liu, Xueli, Ma, Wendy, DiRienzo, Christine G., Chan, Geoffrey, Cortes, Jorge E.

Volltext

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study von Czuczman, Myron S., Fayad, Luis, Delwail, Vincent, Cartron, Guillaume, Jacobsen, Eric, Kuliczkowski, Kazimierz, Link, Brian K., Pinter-Brown, Lauren, Radford, John, Hellmann, Andrzej, Gallop-Evans, Eve, DiRienzo, Christine G., Goldstein, Nancy, Gupta, Ira, Jewell, Roxanne C., Lin, Thomas S., Lisby, Steen, Schultz, Martin, Russell, Charlotte A., Hagenbeek, Anton

Volltext

Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials von Cortes, Jorge E, Dombret, Hervé, Merchant, Akil, Tauchi, Tetsuzo, DiRienzo, Christine G, Sleight, Barbara, Zhang, Xiaoxi, Leip, Eric P, Shaik, Naveed, Bell, Timothy, Chan, Geoffrey, Sekeres, Mikkael A

Volltext

A phase 2 study of ofatumumab in Waldenström’s macroglobulinaemia von Furman¹, Richard R, Eradat, Herbert A, DiRienzo, Christine G, Hofmeister, Craig C, Hayman, Suzanne R, Leonard, John P, Coleman, Morton, Advani, Ranjana, Chanan-Khan, Asher, Switzky, Julie, Liao, Qiming M, Shah, Damini, Jewell, Roxanne C, Lisby, Steen, Lin, Thomas S

Volltext

T-Cell Receptor Vα Usage by Effector CD4+ Vβ11+ T Cells Mediating Graft-versus-Host Disease Directed to Minor Histocompatibility Antigens von DiRienzo, Christine G, Murphy, George F, Friedman, Thea M, Korngold, Robert

Volltext

T-Cell Receptor Vα Spectratype Analysis of a CD4-Mediated T-Cell Response against Minor Histocompatibility Antigens Involved in Severe Graft-versus-Host Disease von DiRienzo, Christine G., Murphy, George F., Jones, Stephen C., Korngold, Robert, Friedman, Thea M.

Volltext

TCRVα usage by effector CD4+Vβ11+ T cells mediating graft-versus-host disease directed to minor histocompatibility antigens von DiRienzo, Christine G., Murphy, George F., Friedman, Thea M., Korngold, Robert

Volltext

T-cell receptor V(alpha) usage by effector CD4+Vbeta11+ T cells mediating graft-versus-host disease directed to minor histocompatibility antigens von DiRienzo, Christine G, Murphy, George F, Friedman, Thea M, Korngold, Robert

Volltext

T-cell receptor Valpha spectratype analysis of a CD4-mediated T-cell response against minor histocompatibility antigens involved in severe graft-versus-host disease von DiRienzo, Christine G, Murphy, George F, Jones, Stephen C, Korngold, Robert, Friedman, Thea M

Volltext

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment von Haubrich, Richard H, Riddler, Sharon A, DiRienzo, A Gregory, Komarow, Lauren, Powderly, William G, Klingman, Karin, Garren, Kevin W, Butcher, David L, Rooney, James F, Haas, David W, Mellors, John W, Havlir, Diane V

Volltext